|
| Wednesday, October 9, 2024 |
|
|
CanSino Receives Another Strong Boost |
| CanSino Biologics Inc. ("CanSinoBIO" or "the Company") has announced a milestone in its fight against polio. more info >> |
|
| Thursday, August 29, 2024 |
|
|
CanSinoBIO Reports Outstanding H1 2024 Performance |
| CanSino Biologics Inc. (CanSinoBIO) today disclosed its performance report for the first half of 2024, with revenue reaching 303 million yuan, while losses were substantially reduced. more info >> |
|
|
康希諾生物2024上半年業績亮眼：流腦疫苗引領增長，加快合作與國際化步伐 |
| 康希諾生物今日披露了2024年上半年業績報告，營收達到3.03億元，其中流腦結合疫苗家族再度展現强勁增長動力，尤其是ACYW135群腦膜炎球菌多糖結合疫苗（CRM197載體）（以下簡稱“MCV4”）曼海欣®作爲亞洲首個腦膜炎球菌四價結合疫苗産品，不僅填補了市場空白，更爲我國嬰幼兒流腦疾病預防樹立了新標杆。 more info >> |
|
|
康希诺生物2024上半年业绩亮眼：流脑疫苗引领增长，加快合作与国际化步伐 |
| 康希诺生物今日披露了2024年上半年业绩报告，营收达到3.03亿元，其中流脑结合疫苗家族再度展现强劲增长动力，尤其是ACYW135群脑膜炎球菌多糖结合疫苗（CRM197载体）（以下简称“MCV4”）曼海欣®作为亚洲首个脑膜炎球菌四价结合疫苗产品，不仅填补了市场空白，更为我国婴幼儿流脑疾病预防树立了新标杆。 more info >> |
|
| Friday, April 26, 2024 |
|
|
CanSinoBIO CSO Shares Latest Results of the Company's Globally Innovative Pneumococcal Vaccine |
| On April 20, the 2024 National Vaccines and Health Conference organized by the Chinese Preventive Medicine Association (CPMA) and the Chinese Center for Disease Control and Prevention (China CDC) took place in the Xiong'an New Area of Hebei Province. more info >> |
|
| Wednesday, March 27, 2024 |
|
|
来自康希诺生物的亚洲首个流脑结合疫苗商业化取得巨大突破 |
| 2023年，康希诺流脑结合疫苗实现营业收入约56,172.4万元，较去年同期增长约266.39%，增长趋势明显。 more info >> |
|
|
來自康希諾生物的亞洲首個流腦結合疫苗商業化取得巨大突破 |
| 2023年，康希諾流腦結合疫苗實現營業收入約56,172.4萬元，較去年同期增長約266.39%，增長趨勢明顯。 more info >> |
|
|
The Commercialization of Asia's First Meningococcal Conjugate Vaccine From CanSinoBIO Represents a Significant Breakthrough |
| In 2023, CanSinoBIO's meningococcal conjugate vaccine achieved revenue approximately RMB561.72 million, representing a year-on-year increase of approximately 266.39% compared to last year. The growth trend is evident. more info >> |
|
|
|
|
